FDA Clears Abbisko's FGFR Inhibitor for Achondroplasia as BridgeBio Reports Phase 3 Success
Apr 01, 2026
The FDA has cleared Abbisko Therapeutics' IND application for ABSK061, an oral FGFR2/3 inhibitor for achondroplasia, while BridgeBio reports positive Phase 3 results for its oral infigratinib in the same condition. Both companies are advancing oral therapies targeting FGFR3 overactivity in this genetic growth disorder.